Trump Announces Drug-Pricing Deals With Nine More Pharmaceutical Companies, Claims $600B in Savings

President Trump announced at the White House on Monday, August 31, 2026, that his administration reached 'most-favored-nation' drug-pricing agreements with nine additional pharmaceutical manufacturers — Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB — bringing the total to 26 companies representing roughly 90% of the domestic pharmaceutical market. The companies pledged to offer new medications to state Medicaid programs at prices comparable to peer countries' lowest prices, sell discounted drugs via the TrumpRx website, and commit $19.6 billion to domestic manufacturing. Trump said the deals are 'projected to save Americans more than $600 billion' over a short period, though the Council of Economic Advisers' 10-year savings projection has not been independently verified.